Showing papers by "King Faisal Specialist Hospital & Research Centre published in 2021"
••
TL;DR: Most haematologists have little knowledge of radiation biology and should consider updating this aspect of their expertise in continuing medical education and be active in decreasing risks of a nuclear war.
Abstract: Bone marrow damage is an important consequence of exposure to acute high-dose whole-body radiation. As such, haematologists can play an important role in managing this complication. However, these accident and incident scenarios are complex and often involve injuries to other organs and tissues from heat, projectiles and chemicals. In the case of a large-scale event there will likely be severe infrastructure disruptions and injury or death to medical personnel. Accurate estimates of dose and uniformity of exposure are needed to intelligently direct appropriate interventions, which range from antibiotics, antifungals and anti-virus drugs, molecularly-cloned haematopoietic growth factors and, in rare instances, haematopoietic cell transplants. These therapies are ones that haematologists often use in the context of anti-cancer therapy, especially therapy of haematological cancers like leukaemia. However, most haematologists have little knowledge of radiation biology and should consider updating this aspect of their expertise in continuing medical education. As in other areas of medicine, prevention is better than cure and haematologists should be active in decreasing risks of a nuclear war.
15 citations
••
King Faisal Specialist Hospital & Research Centre1, Yahoo!2, King Saud University3, Cleveland Clinic4, King Abdulaziz Medical City5, Tanta University6, King Abdulaziz University7, King Fahad Specialist Hospital8, Sultan Qaboos University9, Adan Hospital10, IBN Sina Medical College11, Banha University12, National Institutes of Health13, Tufts University14
TL;DR: In this article, the authors evaluated clinical outcomes of ULMCA PCI as compared to CABG in patients requiring revascularization in three Gulf countries, and found that no difference was observed in freedom from revascularisation, major adverse cardiovascular and cerebrovascular events (MACCE) or total mortality between those treated with PCI and CabG.
4 citations
••
TL;DR: In this article, the authors report the case of a 47-year-old female with thyroid cancer who underwent total thyroidectomy followed by radioiodine ablation, and developed noniodine-avid renal and pulmonary metastases.
Abstract: Background The management of metastatic progressive radioiodine-resistant differentiated thyroid cancer remains challenging for clinicians. The availability of tyrosine kinase inhibitors (TKIs), sorafenib and lenvatinib, within the last decade has expanded treatment options; however, these lead to significant adverse effects, which may curtail their use. Case summary We report the case of a 47-year-old female with Hurthle cell thyroid cancer who underwent total thyroidectomy followed by radioiodine ablation. During follow-up, she developed noniodine-avid renal and pulmonary metastases. With respect to her pre-existing diabetes, hypertension, and polycystic kidney disease, the tumor board decided against performing renal metastasectomy because of the risk of future renal decline requiring dialysis. Metastases were treated using sorafenib, which provided stability followed by progression within a year. We switched to lenvatinib, which led to disease regression. However, the patient experienced severe adverse effects, including cardiomyopathy, bicytopenia, renal impairment, and the rarely reported nephrotic syndrome. Renal metastasis is a rare manifes-tation of Hurthle cell thyroid cancer with only two reported cases in literature. We report the experience of our first case of renal metastasis and its treatment with TKIs. This case serves as a reminder of the adverse drug reactions associated with TKI use. Conclusion We advocate close monitoring of patients' hematological and renal profiles as well as their cardiac status using an echocardiogram.
1 citations